Abstract: A polypeptide having superoxide dismutase (SOD) activity and/or extracellular vesicles containing SOD is effective for the prevention and/or treatment of respiratory viral infection or diseases caused by respiratory viral infection in a subject. The polypeptide has SOD activity derived from a Bacillus amyloliquefaciens strain and/or extracellular vesicles containing SOD derived from a Bacillus subtillis strain is useful for the prevention and/or treatment of respiratory viral infection or diseases caused by respiratory viral infection in a subject.

Abstract: The present invention relates, in part, to methods of preventing or treating macular degeneration in a subject by co-administering a superoxide dismutase enzyme and probiotic Bacillus sp. spores, especially a Bacillus amyloliquefaciens GF423 or GF424 mutant strain. The present invention also provides pharmaceutical and/or food compositions comprising a superoxide dismutase enzyme and probiotic Bacillus sp. spores.

Abstract: The present invention relates to a signal sequence for expressing a CRM197 protein in Escherichia coli and secreting same into the periplasm, and a use thereof, and more specifically, to: a signal sequence for expressing a CRM197 protein; a nucleic acid for coding the signal sequence; a nucleic acid construct or expression vector comprising the nucleic acid and a CRM197 protein gene; a recombinant microorganism having the nucleic acid construct or expression vector introduced therein; and a CRM197 protein production method comprising a step for culturing the recombinant microorganism.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating inflammatory disease, which contains, as an active ingredient, a Bacillus amyloliquefaciens GF423 strain, a superoxide dismutase high-producing Bacillus amyloliquefaciens GF424 mutant strain, a superoxide dismutase (SOD) derived from one of these strains, or both the strain and the SOD. The superoxide dismutase derived from the Bacillus amyloliquefaciens GF423 strain (KCTC 13222BP), which is the active ingredient of the present invention, effectively suppresses or degrades reactive oxygen species, and thus has the effect of fundamentally preventing the causes of inflammatory bowel disease caused by reactive oxygen species. Therefore, the composition of the present invention may be developed into various products, including excellent drugs and health functional foods for preventing or treating inflammatory bowel disease.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating inflammatory disease, which contains, as an active ingredient, a Bacillus amyloliquefaciens GF423 strain, a superoxide dismutase high-producing Bacillus amyloliquefaciens GF424 mutant strain, a superoxide dismutase (SOD) derived from one of these strains, or both the strain and the SOD. The superoxide dismutase derived from the Bacillus amyloliquefaciens GF423 strain (KCTC 13222BP), which is the active ingredient of the present invention, effectively suppresses or degrades reactive oxygen species, and thus has the effect of fundamentally preventing the causes of inflammatory bowel disease caused by reactive oxygen species. Therefore, the composition of the present invention may be developed into various products, including excellent drugs and health functional foods for preventing or treating inflammatory bowel disease.

Abstract: The present invention relates to a Bacillus amyloliquefaciens strain that produces superoxide dismutase (SOD), and also relates to an antioxidant, anti-inflammatory pharmaceutical composition and a pharmaceutical composition and food composition for preventing or treating hyperlipidemia, which include a superoxide dismutase produced by the Bacillus amyloliquefaciens strain. The compositions of the present invention exhibit excellent effects without causing side effects, and may thus be used as functional raw materials or products having an enhanced activity of preventing or treating inflammation, cancer or hyperlipidemia in the pharmaceutical drug, food, cosmetic and livestock fields.

Abstract: The present invention relates to a beta-galactosidase mutant having high transglycosylation activity and containing a C-terminal deletion, and the use thereof and more. More specifically, the present invention relates to a beta-galactosidase mutant having a C-terminal deletion, a gene encoding the same, a recombinant vector containing the gene, a recombinant microorganism transformed with the gene or the recombinant vector, and a method for producing the beta-galactosidase mutant using the recombinant microorganism. Using the high transglycosylation activity of the beta-galactosidase mutant containing the C-terminal deletion according to the present invention, galactooligosaccharide can be efficiently produced in large amounts.

Abstract: The present invention relates to a Bacillus amyloliquefaciens strain that produces superoxide dismutase (SOD), and also relates to an antioxidant, anti-inflammatory pharmaceutical composition and a pharmaceutical composition and food composition for preventing or treating hyperlipidemia, which include a superoxide dismutase produced by the Bacillus amyloliquefaciens strain. The compositions of the present invention exhibit excellent effects without causing side effects, and may thus be used as functional raw materials or products having an enhanced activity of preventing or treating inflammation, cancer or hyperlipidemia in the pharmaceutical drug, food, cosmetic and livestock fields.

Abstract: The present invention relates to a novel alpha-1,3-glucanase, and more particularly, to a novel alpha-1,3-glucanase from Trichoderma harzianum, a gene encoding the same, a recombinant vector and recombinant microorganism comprising the gene, and a method of producing an alpha-1,3-glucanase using the recombinant microorganism. The novel alpha-1,3-glucanase according to the present invention can effectively degrade mutan, which is a component of a microbial biofilm, and thus it can be used in oral hygiene products and the medical field.

Abstract: The present invention relates to a novel beta-galactosidase, and more particularly to a novel beta-galactosidase derived from Bacillus circulans, a gene encoding the beta-galactosidase, a recombinant vector and a recombinant microorganism, which contain the gene, a method for producing a beta-galactosidase using the recombinant microorganism, and a method for producing galactooligosaccharide using the beta-galactosidase. The use of the novel beta-galactosidase according to the present invention makes it possible to efficiently produce a large amount of galactooligosaccharide.

Abstract: The present invention relates to a novel alpha-1,3-glucanase, and more particularly, to a novel alpha-1,3-glucanase from Trichoderma harzianum, a gene encoding the same, a recombinant vector and recombinant microorganism comprising the gene, and a method of producing an alpha-1,3-glucanase using the recombinant microorganism. The novel alpha-1,3-glucanase according to the present invention can effectively degrade mutan, which is a component of a microbial biofilm, and thus it can be used in oral hygiene products and the medical field.

Abstract: The present invention relates to a beta-galactosidase mutant having high transglycosylation activity and containing a C-terminal deletion, and the use thereof and more. More specifically, the present invention relates to a beta-galactosidase mutant having a C-terminal deletion, a gene encoding the same, a recombinant vector containing the gene, a recombinant microorganism transformed with the gene or the recombinant vector, and a method for producing the beta-galactosidase mutant using the recombinant microorganism. Using the high transglycosylation activity of the beta-galactosidase mutant containing the C-terminal deletion according to the present invention, galactooligosaccharide can be efficiently produced in large amounts.

Abstract: The present invention relates to a novel beta-galactosidase, and more particularly to a novel beta-galactosidase derived from Bacillus circulans, a gene encoding the beta-galactosidase, a recombinant vector and a recombinant microorganism, which contain the gene, a method for producing a beta-galactosidase using the recombinant microorganism, and a method for producing galactooligosaccharide using the beta-galactosidase. The use of the novel beta-galactosidase according to the present invention makes it possible to efficiently produce a large amount of galactooligosaccharide.

Abstract: The present invention relates to a method for modulating thermostability or acid tolerance of a microbe by mutating a nucleic acid molecule encoding a homoserine o-succinyltransferase (MetA) to obtain a nucleic acid molecule encoding a mutant MetA and transforming a microbial cell with the nucleic acid molecule encoding a mutant MetA. The microbe, a bacteria expressing the mutant MetA of the present invention represents a growth rate improved in a vigorous environment such as higher-temperatures and/or lower pH conditions.

Abstract: Disclosed herein are ammonia-specific 5?-XMP aminase mutants and a method for preparing the same. A mutation is introduced into the active site of glutamine-dependent catalysis in 5?-XMP aminase. The resulting 5?-XMP aminase mutant is devoid of the glutamine-dependent activity and specifically reacts with external ammonia in converting 5?-XMP into 5?-GMP. Thus, the ammonia-specific 5?-XMP aminase mutant is stabler within cells compared to the wild type, and can be useful in the industrial conversion of 5?-XMP into 5?-GMP.

Abstract: The present invention relates to a method for expressing a target protein on an exosporium forming the outermost surface of bacterial spores. More particularly, the present invention relates to a method for expressing a target protein on the surface of cells and spores using an exosporium as a matrix for surface expression, and methods for the production of a protein array, the production of antibodies, the separation of a certain substance from a mixture, bioconversion, and the improvement of a target protein, which are characterized by using the cells or spores having the target protein that was expressed on the surface by the above expression method.

Abstract: The present invention relates to a method of protein synthesis and, more particularly, to a method of effective protein synthesis by regulating the expression of a protein in a host cell, wherein said host cell is transformed with an expression vector comprising a promoter as well as a DNA fragment for a gene that encodes a desired protein, wherein said promoter has an inductive activity for transcription during the resting stage of cell growth and also the induction of said protein expression can be controlled by varying culturing conditions.

Abstract: The present invention relates a method for modulating thermostability or acid tolerance of a microbe, comprising the steps of: (a) conferring a substitution mutation to a homoserine o-succinyltransferase (MetA)-encoding nucleotide sequence; and (b) transforming the MetA-encoding nucleotide sequence into a microbial cell. The mutated MetA of the present invention shows stability notably enhanced at high-temperatures and/or under acid conditions or decreased at mild temperature, and the microbe, particular bacteria expressing the mutated MetA of the present invention represents a growth rate improved in a vigorous environment such as higher-temperatures and/or lower acid conditions.

Abstract: The present invention relates to a method for display of proteinson spore surface and a method for improving protein with rapidity using the same, which comprises the steps of (i) preparing a vector for spore surface display comprising a gene construct containing a gene encoding spore coat protein and a gene encoding a protein of interest, wherein, when expressed, the gene construct expresses a fusion protein between the spore coat protein and the protein of interest, (ii) transforming a host cell with the vector for spore surface display; (iii) displaying the protein of interest on a surface of a spore of the host cell; and (iv) recovering the spore displaying on its surface the protein of interest.

Abstract: Disclosed herein are ammonia-specific 5?-XMP aminase mutants and a method for preparing the same. A mutation is introduced into the active site of glutamine-dependent catalysis in 5?-XMP aminase. The resulting 5?-XMP aminase mutant is devoid of the glutamine-dependent activity and specifically reacts with external ammonia in converting 5?-XMP into 5?-GMP. Thus, the ammonia-specific 5?-XMP aminase mutant is stabler within cells compared to the wild type, and can be useful in the industrial conversion of 5?-XMP into 5?-GMP.